New drugs other than the JAK inhibitors for MF
| Agent . | Drug class . | Phase . |
|---|---|---|
| Pomalidomide | Immunomodulator | 3 (withdrawn) |
| Azacitidine | Hypomethylating agent | 2 |
| Decitabine | Hypomethylating agent | 1-2 |
| Givinostat | Histone deacetylase inhibitor | 2 |
| Panobinostat | Histone deacetylase inhibitor | 2 |
| Everolimus | m-TOR inhibitor | 2 |
| Obatoclax mesylate | Bcl-2 inhibitor | 2 |
| AUY-922 | HSP90 inhibitor | 2 |
| PF-04449913 | Hedgehog inhibitor | 2 |
| PRM-151 | Anti-fibrosis agent | 2 |
| GC-1008 | Anti-fibrosis agent | 1 |
| GS-6624 | Anti-fibrosis agent | 1 |
| Imetelstat | Telomerase inhibitor | 1-2 |
| IPI-926 | Hedgehog inhibitor | 1 |
| LDE-225 | Hedgehog inhibitor | 1 |
| BKM-120 | PI3K/AKT inhibitor | 1 |
| MK-2206 | PI3K/AKT inhibitor | Preclinical |
| ABT-737 | BCL-XL inhibitor | Preclinical |
| PU-H71 | HSP90 inhibitor | Preclinical |
| Agent . | Drug class . | Phase . |
|---|---|---|
| Pomalidomide | Immunomodulator | 3 (withdrawn) |
| Azacitidine | Hypomethylating agent | 2 |
| Decitabine | Hypomethylating agent | 1-2 |
| Givinostat | Histone deacetylase inhibitor | 2 |
| Panobinostat | Histone deacetylase inhibitor | 2 |
| Everolimus | m-TOR inhibitor | 2 |
| Obatoclax mesylate | Bcl-2 inhibitor | 2 |
| AUY-922 | HSP90 inhibitor | 2 |
| PF-04449913 | Hedgehog inhibitor | 2 |
| PRM-151 | Anti-fibrosis agent | 2 |
| GC-1008 | Anti-fibrosis agent | 1 |
| GS-6624 | Anti-fibrosis agent | 1 |
| Imetelstat | Telomerase inhibitor | 1-2 |
| IPI-926 | Hedgehog inhibitor | 1 |
| LDE-225 | Hedgehog inhibitor | 1 |
| BKM-120 | PI3K/AKT inhibitor | 1 |
| MK-2206 | PI3K/AKT inhibitor | Preclinical |
| ABT-737 | BCL-XL inhibitor | Preclinical |
| PU-H71 | HSP90 inhibitor | Preclinical |